Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01866865 · ClinicalTrials.gov registry record
Adaptation to Living With a BRCA1/2 Mutation
A clinical trial, sponsored by National Human Genome Research Institute (NHGRI).
- Completed
- Registry status
- 142
- Enrollment target
NCT01866865: Completed study, sponsored by National Human Genome Research Institute (NHGRI).
NCT01866865 is a clinical trial that has completed, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 142 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01866865 has completed, sponsored by National Human Genome Research Institute (NHGRI).
- COMPLETED
- Registry status
- 142 participants
- Enrollment target
Study Summary
Background: \- Women who have a BRCA1/2 gene mutation have a very high risk of developing breast or ovarian cancer. They are also at increased risk of other developing other cancers. Male carriers are at increased risk for breast, prostate and other cancers. Testing for this mutation and living with this increased risk can be a source of stress for both people with the mutation and their partners. Researchers want to look at how well people adapt to living with this type of cancer risk over time. Objectives: \- To see how women with the BRCA1/2 gene mutation and their partners adapt to the stress of long-term cancer risk. Eligibility: \- Women at least 18 years of age who have a BRCA1/2 mutation, and their male or female partners. Design: * This study involves a one-time self-administered questionnaire. Participants will be recruited from local and national hereditary cancer support groups and cancer centers. * There are two versions of the survey. One is for the woman with the BRCA1/2 gene mutation. The other is for her partner. * The survey will ask about risk perception, cancer worry, risk-related stress, and coping and adaptation methods. * Treatment will not be provided as part of this study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2013-05-02 |
| Est. Completion | 2014-02-20 |
What the finished NCT01866865 record still lists
NCT01866865 is an observational study that tracks outcomes without assigning an intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01866865 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01866865 about?
NCT01866865 is a clinical study titled "Adaptation to Living With a BRCA1/2 Mutation". Background: \- Women who have a BRCA1/2 gene mutation have a very high risk of developing breast or ovarian cancer. They are also at increased risk of other developing other cancers. Male carriers are at increased risk for breast, prostate and other cancers. Testing for this mutation and living wit...
What is the current status of trial NCT01866865?
This trial is currently completed. The enrollment target is 142 participants. The study started on 2013-05-02. Estimated completion is 2014-02-20.
Who is sponsoring clinical trial NCT01866865?
This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI